Literature DB >> 31659098

MicroRNA 362-3p Reduces hERG-related Current and Inhibits Breast Cancer Cells Proliferation.

Abdullah A Assiri1,2, Noha Mourad1,3, Minghai Shao1, Patrick Kiel4, Wanqing Liu5, Todd C Skaar4, Brian R Overholser6,4.   

Abstract

BACKGROUND/AIM: hERG potassium channels enhance tumor invasiveness and breast cancer proliferation. MicroRNA (miRNA) dysregulation during cancer controls gene regulation. The objective of this study was to identify miRNAs that regulate hERG expression in breast cancer.
MATERIALS AND METHODS: Putative miRNAs targeting hERG were identified by bioinformatic approaches and screened using a 3'UTR luciferase assay. Functional assessments of endogenous hERG regulation were made using whole-cell electrophysiology, proliferation assays, and cell-cycle analyses following miRNA, hERG siRNA, or control transfection.
RESULTS: miR-362-3p targeted hERG 3'UTR and was associated with higher survival rates in patients with breast cancer (HR=0.39, 95%CI=0.18-0.82). Enhanced miR-362-3p expression reduced hERG expression, peak current, and cell proliferation in cultured breast cancer cells (p<0.05).
CONCLUSION: miR-362-3p mediates the transcriptional regulation of hERG and is associated with survival in breast cancer. The potential for miR-362-3p to serve as a biomarker and inform therapeutic strategies warrants further investigation. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  MicroRNA; breast cancer; hERG; miR-362-3p; voltage-gated potassium channels

Mesh:

Substances:

Year:  2019        PMID: 31659098      PMCID: PMC6885367          DOI: 10.21873/cgp.20147

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  38 in total

1.  The potent inhibitory effects of cisapride, a specific blocker for human ether-a-go-go-related gene (HERG) channel, on gastric cancer cells.

Authors:  Xiao-Dong Shao; Kai-Chun Wu; Zhi-Ming Hao; Liu Hong; Jing Zhang; Dai-Ming Fan
Journal:  Cancer Biol Ther       Date:  2005-03-20       Impact factor: 4.742

2.  miR-362-3p regulates cell proliferation, migration and invasion of trophoblastic cells under hypoxia through targeting Pax3.

Authors:  Nan Wang; Yaling Feng; Jianjuan Xu; Jinfang Zou; Minghua Chen; Yue He; Huan Liu; Min Xue; Yanfang Gu
Journal:  Biomed Pharmacother       Date:  2018-02-20       Impact factor: 6.529

Review 3.  Expression and role of hERG channels in cancer cells.

Authors:  Annarosa Arcangeli
Journal:  Novartis Found Symp       Date:  2005

Review 4.  MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.

Authors:  Rajesha Rupaimoole; Frank J Slack
Journal:  Nat Rev Drug Discov       Date:  2017-02-17       Impact factor: 84.694

5.  Downregulation of microRNA-362-3p and microRNA-329 promotes tumor progression in human breast cancer.

Authors:  H Kang; C Kim; H Lee; J G Rho; J-W Seo; J-W Nam; W K Song; S W Nam; W Kim; E K Lee
Journal:  Cell Death Differ       Date:  2015-09-04       Impact factor: 15.828

6.  Selective expression of HERG and Kv2 channels influences proliferation of uterine cancer cells.

Authors:  Takahiro Suzuki; Koichi Takimoto
Journal:  Int J Oncol       Date:  2004-07       Impact factor: 5.650

7.  herg1b expression as a potential specific marker in pediatric acute myeloid leukemia patients with HERG 897K/K genotype.

Authors:  Merve Erdem; Tugce Ayca Tekiner; Arta Fejzullahu; Gokce Akan; Sema Anak; Ebru Tugrul Saribeyoglu; Ugur Ozbek; Fatmahan Atalar
Journal:  Pediatr Hematol Oncol       Date:  2014-09-23       Impact factor: 1.969

8.  Inhibition of HERG1 K+ channel protein expression decreases cell proliferation of human small cell lung cancer cells.

Authors:  Günter Glassmeier; Kathrin Hempel; Iris Wulfsen; Christiane K Bauer; Udo Schumacher; Jürgen R Schwarz
Journal:  Pflugers Arch       Date:  2011-11-11       Impact factor: 3.657

Review 9.  The role of MicroRNAs in human cancer.

Authors:  Yong Peng; Carlo M Croce
Journal:  Signal Transduct Target Ther       Date:  2016-01-28

Review 10.  hERG channel function: beyond long QT.

Authors:  Joseph J Babcock; Min Li
Journal:  Acta Pharmacol Sin       Date:  2013-03       Impact factor: 6.150

View more
  11 in total

1.  LncRNA MALAT1 inhibits the proliferation and invasiveness of laryngeal squamous cell carcinoma Hep-2 cells by modulating miR-362-3p.

Authors:  Baotong Xie; Zhaohua Wang; Tao Li; Junfang Xue; Chunming Zhang
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

2.  The Effectiveness of Isoplumbagin and Plumbagin in Regulating Amplitude, Gating Kinetics, and Voltage-Dependent Hysteresis of erg-mediated K+ Currents.

Authors:  Linyi Chen; Hsin-Yen Cho; Tzu-Hsien Chuang; Ting-Ling Ke; Sheng-Nan Wu
Journal:  Biomedicines       Date:  2022-03-27

Review 3.  Pathophysiological role of ion channels and transporters in HER2-positive breast cancer.

Authors:  Zhengxing Zhou; Chengmin Zhang; Zhiyuan Ma; Hu Wang; Biguang Tuo; Xiaoming Cheng; Xuemei Liu; Taolang Li
Journal:  Cancer Gene Ther       Date:  2022-01-07       Impact factor: 5.854

4.  SP1/AKT/FOXO3 Signaling Is Involved in miR-362-3p-Mediated Inhibition of Cell-Cycle Pathway and EMT Progression in Renal Cell Carcinoma.

Authors:  Hejia Zhu; Song Wang; Haixiang Shen; Xiangyi Zheng; Xin Xu
Journal:  Front Cell Dev Biol       Date:  2020-05-05

5.  miR-362-3p acts as a tumor suppressor by targeting SERBP1 in ovarian cancer.

Authors:  Shujun Cao; Na Li; Xihong Liao
Journal:  J Ovarian Res       Date:  2021-02-01       Impact factor: 4.234

6.  The molecular mechanisms of the long noncoding RNA SBF2-AS1 in regulating the proliferation of oesophageal squamous cell carcinoma.

Authors:  Wenjuan Zha; Xiaomin Li; Xiaowei Tie; Yao Xing; Hao Li; Fei Gao; Ting Ye; Wangqi Du; Rui Chen; Yangchen Liu
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

Review 7.  miRNA-based biomarkers, therapies, and resistance in Cancer.

Authors:  Boxue He; Zhenyu Zhao; Qidong Cai; Yuqian Zhang; Pengfei Zhang; Shuai Shi; Hui Xie; Xiong Peng; Wei Yin; Yongguang Tao; Xiang Wang
Journal:  Int J Biol Sci       Date:  2020-07-19       Impact factor: 6.580

8.  MiR-362 suppresses cervical cancer progression via directly targeting BAP31 and activating TGFβ/Smad pathway.

Authors:  Shuya Yang; Yuanjie Sun; Dongbo Jiang; Jing Wang; Erle Dang; Zichao Li; Jiayi Zhou; Yuchen Lu; Jingqi Shi; Liang Tao; Jun Wang; Boquan Jin; Lianhe Zheng; Kun Yang
Journal:  Cancer Med       Date:  2020-11-19       Impact factor: 4.452

9.  Pan-cancer characterization of metabolism-related biomarkers identifies potential therapeutic targets.

Authors:  Guoshu Bi; Yunyi Bian; Jiaqi Liang; Jiacheng Yin; Runmei Li; Mengnan Zhao; Yiwei Huang; Tao Lu; Cheng Zhan; Hong Fan; Qun Wang
Journal:  J Transl Med       Date:  2021-05-24       Impact factor: 5.531

10.  Aberrant miR-362-3p is Associated with EBV-Infection and Prognosis in Nasopharyngeal Carcinoma and Involved in Tumor Progression by Targeting JMJD2A.

Authors:  Xiangyun Wang; Ping Chen
Journal:  Onco Targets Ther       Date:  2022-01-28       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.